References
- Barbato A. Schizophrenia and public health. Division of Mental Health and Prevention of Substance Abuse, World Health Organization; 1998. p. 6–7
- Bebbington PE. The content and context of compliance. Int Clin Psychopharmacol 1995;9(Suppl 5):41–50
- Fenton WS, Blyler CR, Heinssen RK. Determinants of medication compliance in schizophrenia: empirical and clinical findings. Schizophr Bull 1997;23:637–51
- Frank AF, Gunderson JG. The role of the therapeutic alliance in the treatment of schizophrenia. Relationship to course and outcome. Arch Gen Psychiatry 1990;47:228–36
- Heikkila L, Eliander H, Vartiainen H, Turunen M, Pedersen V. Zuclopenthixol and haloperidol in patients with acute psychotic states. A double-blind, multi-centre study. Curr Med Res Opin 1992;12:594–603
- Burns T, Bale R. Clinical advantages of amisulpride in the treatment of acute schizophrenia. J Int Med Res 2001;29:451–66
- Möller HJ, Bauml J, Ferrero F, et al. Risperidone in the treatment of schizophrenia: results of a study of patients from Germany, Austria, and Switzerland. Eur Arch Psychiatry Clin Neurosci 1997;247:291–6
- Huttunen MO, Piepponen T, Rantanen H, Larmo I, Nyholm R, Raitasuo V. Risperidone versus zuclopenthixol in the treatment of acute schizophrenia episodes: a double-blind parallel-group trial. Acta Psychiatr Scand 1995;91:271–7
- Osser DN, Sigadel R. Short-term inpatient pharmacotherapy of schizophrenia. Harv Rev Psychiatry 2001;9:89–104
- Borison RL, Arvanitis LA, Miller BG, the US Seroquel Study Group. ICI 204,636, an atypical antipsychotic: efficacy and safety in a multicenter, placebo-controlled trial in patients with schizophrenia. J Clin Psychopharmacol 1996;16: 158–69
- Small JG, Hirsch SR, Arvanitis LA, Miller BG, Link CG, the Seroquel Study Group. Quetiapine in patients with schizophrenia. A high- and low-dose double-blind comparison with placebo. Arch Gen Psychiatry 1997;54:549–57
- Arvanitis LA, Miller BG, the Seroquel Trial 13 study group. Multiple fixed doses of ‘Seroquel’ (quetiapine) in patients with acute exacerbation of schizophrenia: a comparison with haloperidol and placebo. Biol Psychiatry 1997;42: 233–46
- Whitehead A, Whitehead J. A general parametric approach to the meta-analysis of randomized clinical trials. Stat Med 1991;10:1665–77
- Mullen J, Jibson MD, Sweitzer D, for the QUEST Study Group. A comparison of the relative safety, efficacy, and tolerability of quetiapine and risperidone in outpatients with schizophrenia and other psychotic disorders: the Quetiapine Experience with Safety and Tolerability (QUEST) study. Clin Ther 2001;23:1839–54
- Zhong X, Sweitzer D, Russo J, Otter L, Mullen J. A comparison of the efficacy and safety of quetiapine and risperidone. Eur Neuropsychopharmacol 2003;13:S340
- Velligan DI, Newcomer J, Pultz J, et al. Does cognitive function improve with quetiapine in comparison to haloperidol? Schizophr Res 2002;53:239–48
- Rabinowitz J, Hornik T, Davidson M. Rapid onset of therapeutic effect of risperidone versus haloperidol in a double-blind randomized trial. J Clin Psychiatry 2001;62:343–6
- Tollefson GD, Beasley Jr. CM, Tran PV, et al. Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorders: results of an international collaborative trial. Am J Psychiatry 1997;154:457–65
- Kinon BJ, Roychowdhury SM, Milton DR, Hill AL. Effective resolution with olanzapine of acute presentation of behavioral agitation and positive psychotic symptoms in schizophrenia. J Clin Psychiatry 2001;62(Suppl 2):17–21
- De Nayer A, Windhager E, Irmansyah, et al. on behalf of the SPECTRUM study group. Efficacy and tolerability of quetiapine in patients with schizophrenia switched from other anti-psychotics. Int J Psychiatry Clin Pract 2003;7:59–66
- Smith MA, McCoy R, Hamer J, Brecher M. Optimal titration for quetiapine: pilot trial. American Psychiatric Nurses Association (APNA) Annual Conference, Dallas, Texas, USA, 5–8 October 2002
- Bhana N, Foster RH, Olney R, Plosker GL. Olanzapine. An updated review of its use in the management of schizophrenia. Drugs 2001;61:111–61
- Sussman N. Choosing an atypical antipsychotic. Int Clin Psycho-pharmacol 2002;17(Suppl 3):S29–S33
- Nemeroff CB. Dosing the antipsychotic medication olanzapine. J Clin Psychiatry 1997;58(Suppl 10):45–9
- Allison DB, Mentore JL, Heo M, et al. Antipsychotic-induced weight gain: a comprehensive research synthesis. Am J Psychiatry 1999;156:1686–96
- Brecher M, Rak IW, Melvin K, Jones AM. The long-term effect of quetiapine (Seroquel™) monotherapy on weight in patients with schizophrenia. Int J Psychiatry Clin Pract 2000;4:287–91